Contact us for free information or to start a free case review.
Public Citizen consumer group has been against the approval of Crestor cholesterol drug, citing evidence of increased incidence of rhabdomyolysis, a condition that causes muscle deterioration. The FDA still approved Crestor and said the toxicity was only limited to an 80-milligram dose that was not approved in the end. The newest member of the class of drugs called statins, Crestor has the highest risk for rhabdomyolysis than any other marketed statin, according to the group.
Public Citizen wrote in the June 26, 2004 issue of British medical journal The Lancet that almost 50 people worldwide have suffered serious adverse effects from using Crestor, including two deaths in the U.S. The group had filed a petition with the FDA for the immediate removal of Crestor from the market in March, which is still pending. Crestor is the only statin that showed risk of rhabdomyolysis prior to approval but was still allowed onto the market despite the availability of other statin drugs without the same risks.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.